Kingdon Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Kingdon Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Hold	775,000	–	–	1.14%	31
2026 Q1	$7.22M	Buy	775,000 +189,931	+32%	+$1.71M	0.79%	43
2025 Q4	$5.24M	Sell	585,069 -64,931	-10%	-$614K	0.62%	55
2025 Q3	$6.18M	Buy	650,000 +200,000	+44%	+$2.01M	0.77%	56
2025 Q2	$3.96M	Buy	+450,000	New	+$3.65M	0.53%	56
2016 Q4	–	Sell	-16,248	Closed	-$1.17M	–	160
2016 Q3	$1.17M	Hold	16,248	–	–	0.05%	111
2016 Q2	$1.03M	Buy	16,248 +1,359	+9%	+$224K	0.06%	97
2016 Q1	$3.45M	Buy	14,889 +2,177	+17%	+$527K	0.19%	86
2015 Q4	$4.04M	Sell	12,712 -4,188	-25%	-$1.14M	0.2%	85
2015 Q3	$5.24M	Buy	16,900 +2,837	+20%	+$869K	0.25%	81
2015 Q2	$4.13M	Buy	+14,063	New	+$3.07M	0.16%	104

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kingdon Capital Management's ZVRA Position: Q2 2026 in Review

Kingdon Capital Management held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 775,000 shares worth $11.1M. The position accounts for 1.14% of the portfolio, ranked #31.

Kingdon Capital Management first reported a position in ZVRA in Q2 2015 and has held it in 11 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Kingdon Capital Management held 775,000 shares of Zevra Therapeutics worth $11.1M as of Q2 2026.
Kingdon Capital Management left its Zevra Therapeutics share count unchanged in Q2 2026.
Zevra Therapeutics made up 1.14% of Kingdon Capital Management's portfolio in Q2 2026, its #31 holding.
Kingdon Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 11 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.